Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 10/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484364 | 0.88 | KCNH2 (0.45) | ALDH1A1TRPM8SCN3AKCNH2SCN1A | |
| SCHEMBL5488311 | 0.87 | SCN3A (0.46) | KDM4EGAAKMT2ATRPM8SCN3A | |
| SCHEMBL5482943 | 0.87 | TACR1 (0.47) | MAPTKDM4EMEN1ALDH1A1TP53 | |
| SCHEMBL5489935 | 0.85 | PARP10 (0.56) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL5483694 | 0.85 | SCN3A (0.58) | SCN3AKCNH2SCN1ASCN4ASCN7A | |
| SCHEMBL5484501 | 0.85 | KCNH2 (0.43) | KDM4EALDH1A1GAAKMT2ATRPM8 | |
| SCHEMBL5484369 | 0.84 | KMT2A (0.47) | MAPTKDM4EMEN1GAAKMT2A | |
| SCHEMBL5484837 | 0.84 | SCN3A (0.44) | MEN1KMT2ATRPM8SCN3AKCNH2 | |
| SCHEMBL5483855 | 0.83 | KCNH2 (0.57) | MAPTKDM4EMEN1ALDH1A1GAA | |
| SCHEMBL5481360 | 0.83 | KCNH2 (0.52) | SCN3AKCNH2SCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | claimed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | claimed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | claimed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | claimed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | claimed |
| US-7265244-B2 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-09-04 | — | — | US | disclosed |
| EP-1687259-B1 | CYCLOPENTYL DERIVATES | NEWRON PHARM SPA (IT) | 2007-08-08 | — | — | EP | disclosed |
| US-20070066688-A1 | Cyclopentyl derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-03-22 | — | — | US | disclosed |
| EP-1687259-A1 | CYCLOPENTYL DERIVATES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054178-A1 | CYCLOPENTYL DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1533295-A1 | Cyclopentyl Derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066688-A1 | Cyclopentyl derivatives | HCN3, RYR2, KCNN3 | MCL1 3859/4885MAPT 4030/4885KDM4E 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.